medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (1)

Uric acid in pregnant women diagnosed with sickle cell disease and preeclampsia

Fundora CM, Agramonte LOM, Morales, Miguel MM

Language: Spanish
References: 21
Page: 1-13
PDF size: 262.54 Kb.


ABSTRACT

Introduction: Uric acid is the end product of the purine cycle and is essential as a marker of kidney disease, gout and pre-eclampsia. This biomarker has potential effects on the placenta and fetus of a pregnant woman with sickle cell disease.
Objective: To describe the potential effects of uric acid in pregnant women with sickle cell disease.
Methods: Literature in English and Spanish was reviewed, through the PubMed website and the academic search engine Google, in articles published in the last five years. The search terms were: pre-eclampsia, uric acid and risks in pregnant women with sickle cell disease. The most relevant aspects of the subject were analyzed in the reviewed bibliography.
Analysis and synthesis of information: The increase in uric acid added to vasoocclusion, hypoxia and tissue necrosis at the level of the placenta are mechanisms invoked in the development of pre-eclampsia and the rates of premature births they present. It is noteworthy that it does not have a uniform trajectory in all patients, especially a better evolution is observed, with less presence of these complications in those patients who show a more favorable genotype, fetal hemoglobin levels and hemoglobin S haplotype.
Conclusions: Uric acid constitutes a useful and alarm biomarker in the diagnosis of pre-eclampsia, one of the worst complications both for maternal life and for her offspring, as the pregnant woman with sickle cell disease is a patient at a very high risk of preterm delivery. prematurity, low birth weight, stillbirths and placental infarction.


REFERENCES

  1. Nápoles Méndez D. New interpretations in the classification and diagnosis of pre-eclampsia. MEDISAN. 2016 Abr; 20(4):516-29. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext& pid=S1029-30192016000400013&lng=es.

  2. Álvarez-Ponce V, Rodríguez-Baquero M, Pardo-Mederos J, Rodríguez-Llobera A. El ácido úrico como factor predictor de la preeclampsia. Rev Cubana Obstet Ginecol. 2018;44(2):[aprox.0p.]. Disponible en: http://revginecobstetricia.sld.cu/index.php/gin/article/view/346.

  3. Anuario estadístico de Cuba 2020. ONEI.2021 jul 14[acceso 05/11/2021];0(0):5-28. Disponible en: Disponible en: http://www.onei.gob.cu/node/16275

  4. Escudero C, Bertoglia P, Muñoz F, Roberts James M. Purinas y ácido úrico en pre-eclampsia: interacciones fisiopatológicas y proyecciones en investigación. Rev. méd. Chile. 2013 Jul;141(7):895-902. DOI: http://dx.doi.org/10.4067/S0034-98872013000700009.

  5. Phipps E, Prasanna D, Jim B. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. Clin J Am Soc Nephrol. 2016 Jun;11(6):1102-13. DOI: https://10.2215/CJN.12081115

  6. Yescas Osorio IN, Razo Solano R, Ávila Esquivel JF, Cejudo Álvarez J, Elizalde Valdés VM. Correlación de la concentración sérica de ácido úrico en pacientes con preeclampsia severa en la unidad de cuidados intensivos. Ginecol Obstet Méx. [revista en Internet].2017 [acceso 05/11/2021];85(6):347-54. Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412017000600347&lng=es .

  7. Lin J, Hong XY, Tu RZ. The value of serum uric acid in predicting adverse pregnancy outcomes of women with hypertensive disorders of pregnancy. Ginekologia Polska. 2018;89(7):375-80. DOI: https://10.5603/GP.a2018.0064

  8. Khaliq O, Konoshita T, Moodley J, Naicker T. The role of uric acid in preeclampsia: Is uric acid a causative factor or sing of preeclampsia? Curr Hypertens Rep. 2018 Jul;20(9):70-80. DOI: https://doi.org/10.1007/s11906-018-0878-7

  9. Brien M E, Duval C, Palacios J, Boufaied I. Uric acid crystals induces placental inflammation and alters trophoblast function via an IL-1-dependent pathway: implication for FGR. J Immunol. 2017 Jul;198(1):443-51. DOI: https://doi:10.4049/jimmunol.1601179.

  10. Fernández A, Castelli J, Hernández N, Soldatti L, Hernández J C. Embarazada con preeclampsia: ácido úrico como biomarcador precoz de gravedad. Salud Militar. 2017 Jul;36(2):6-13. DOI: https://dx.doi.org/10.35954/SM2017.36.2.1

  11. Le TM, Nguyen LH, Phan NL, Le DD, Nguyen H. Maternal serum uric acid concentration and pregnancy outcomes in women with pre- eclampsia/eclampsia. Int J Gynecol Obstet. 2019;144: 21-6. DOI: https://doi.org/10.1002/ijgo.12697

  12. Paci Horno HN, Salman Demarchi MA, Pacheco AB, Zamory ES. Ácido úrico como marcador de complicaciones hipertensivas del embarazo. Bioquinforma Digital. 2020;1:17.Disponible en: https://cobico.com.ar/wp-content/archivos/2020/08/14-%c3%81cido-%c3%9arico-como-marcador-de-complicaciones-hipertensivas-del-embarazo.pdf

  13. Martin A, Faes C, Debevec T, Rytz C, Millet G, Pialoux V. Preterm birth and oxidative stress: Effects of acute physical exercise and hypoxia physiological responses. Redox Biol. 2018 Jul; 17:315-22. DOI: https://10.1016/j.redox.2018.04.022

  14. Dávila-Aliaga C. Neonato de madre con preeclampsia: riesgo para toda la vida. Rev Peru Investig Matern Perinat. 2016;5(1):65-9. DOI: https://doi.org/10.33421/inmp.201657

  15. Machín-García S, Svarch E. Drepanocitosis: 50 años de experiencia en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2017 [acceso 02/03/2021];33(S1):[aprox. 0 p.]. Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/633

  16. Díaz-Morejón L, Rodríguez-Jorge B, García-Sánchez D, León-Rayas Y, Aguilar-Lezcano L, Santacruz-Leonard M. Anemia drepanocítica: características generales de los pacientes a su diagnóstico. Rev Finlay. 2019 [acceso 13/04/2019];9(1):[aprox. 6 p.]. Disponible en: Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/681

  17. Svarch E. Fisiopatología de la drepanocitosis. Rev Cubana Hematol Inmunol Hemoter. 2009 Abr [acceso 25/02/2021]; 25(1). Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892009000100003&lng=es .

  18. Elenga N, Adeline A, Balcaen J, Vaz T, Calvez M. Pregnancy in Sickle Cell Disease Is a Very High-Risk Situation: An Observational Study. Obstet Gynecol Int. 2016;2016:9069054. DOI: https://10.1155/2016/9069054

  19. Agramonte Llanes OM, Hernández Pdrón C. Atención hematológica a la embarazada con drepanocitosis en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter. 2016 [acceso 18/02/2021];32(1):[aprox. 0 p.]. Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/306

  20. Agramonte Llanes OM, Hernández Padrón C, Roque García W, Núñez García A. Embarazo en la paciente con drepanocitosis: atención integral en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter. 2016 [acceso 18/02/2021];32(2):[aprox. 0 p.]. Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/408

  21. Cardosa D, Ridout A, Nanda S, Howard J, Robinson SE, Oteng-Ntim E. Maternal sickle cell disease and twin pregnancy: a case series and review of the literature. Hematology. 2019 Dec; 24(1):148-58 DOI: https://10.1080/10245332.2018.1535534




2020     |     www.medigraphic.com